about
Germline mutations in BAP1 predispose to melanocytic tumorsMutations in GNA11 in uveal melanomaSurgical smoke management for minimally invasive (micro)endoscopy: an experimental study.A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.A mathematical model for the deformation of the eyeball by an elastic band.Persistent vitreoretinal adhesion in eyes with peripheral exudative haemorrhagic chorioretinopathy.The occurrence of delayed ocular hypertension and glaucoma after pars plana vitrectomy for rhegmatogenous retinal detachment.Polytetrafluoroethylene (Goretex) for muscle elongation in the surgical treatment of strabismus with restricted motility.Visual outcome and ocular survival after sports related ocular trauma in playing golf.Opacification of a silicone intraocular lens caused by calcium deposits on the optic.Ruthenium-106 plaque brachytherapy for uveal melanoma.A Unifying Concept of Uveal Pigment Cell Distribution and Dissemination Based on an Animal Model: Insights into Ocular Melanogenesis.Circadian macular volume changes in the healthy human choroid.[Dose-volume histogram regression analysis of uveal melanomas after single fraction gamma knife radiosurgery][Dose-effect relation in revision surgery for consecutive strabismus divergens in adults]Misleading axial length measurements with the IOLMaster due to a dense posterior vitreous surface membrane and a macular edema in a diabetic patientNew insights into oculodermal nevogenesis and proposal for a new iris nevus classificationLocal tumour control and eye preservation after gamma-knife radiosurgery of choroidal melanomasOcular trauma scores in paediatric open globe injuriesOzurdex(®) reduces the retinal thickness in radiation maculopathy refractory to bevacizumabResponse of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib
P50
Q24594891-B48CE1DB-B165-486C-941F-1CF9C65C4331Q24625723-DB5633FF-3F1C-44E7-880B-FE7D56CD3096Q33546423-A3204966-7220-483B-BEE4-D44D033CF38EQ35665701-E18D9913-6E25-4703-9FBF-CC7F482C46BFQ41577693-2DC06014-B7BE-426E-AC5E-05582FA33E5FQ46058174-C80FA931-570A-4F02-B947-5022608A09F2Q48222354-280C687A-6CAB-4F7D-A8D2-E8C9C44A7763Q48255040-C047549F-6608-443F-8EAB-24DC4D2C8F3EQ48705218-DA01D631-D72B-4536-97D1-C618C4EF707EQ51678808-0AB3B61E-E808-4337-95FF-DCD44DC8E64DQ51700137-7C78587E-3C89-4387-A7D6-28BDAD6766DAQ53503522-141DDE88-B593-4C7B-A2F9-29AF327DA852Q54393975-0DD933F2-B4F5-4C33-B1D6-D4AC3FECBA08Q54585257-24F25277-5223-48F7-AD95-1001ED6694C5Q80218077-A035793F-34B7-47C4-905D-9887DD1C3B2CQ81624150-F5A16E78-4918-4459-8C76-C7E9E4940DB6Q82314347-B4F09213-44CF-4DF7-8353-BB525B461F6EQ85893676-FFA3027C-A8EF-42D9-BD98-E53B9DE4B960Q86607827-C59C60D8-3CF2-4FA7-BB70-BB70703A6AD9Q87273362-8FFD8D8D-DA91-4A5F-8DF3-3B8B0CD8CBA3Q87695605-CB691364-6D29-41C8-9C32-CF924FB03E7EQ87771389-7DB0FECC-380E-490F-A6BC-423E04074111
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Werner Wackernagel
@ast
Werner Wackernagel
@en
Werner Wackernagel
@es
Werner Wackernagel
@nl
Werner Wackernagel
@sl
type
label
Werner Wackernagel
@ast
Werner Wackernagel
@en
Werner Wackernagel
@es
Werner Wackernagel
@nl
Werner Wackernagel
@sl
prefLabel
Werner Wackernagel
@ast
Werner Wackernagel
@en
Werner Wackernagel
@es
Werner Wackernagel
@nl
Werner Wackernagel
@sl
P106
P1153
9745826200
P21
P31
P496
0000-0002-4524-4012